Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.

Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin CC, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul SA, Gilbert J, Saraf S, Thanigaimani P, Cheng JD, Keam B.

BMC Cancer. 2019 Mar 4;19(1):196. doi: 10.1186/s12885-019-5380-3.

2.

Genomic landscape of a metastatic malignant proliferating tricholemmal tumor and its response to PI3K inhibition.

Gallant JN, Sewell A, Almodovar K, Wang Q, Dahlman KB, Abramson RG, Kapp ME, Brown BT, Boyd KL, Gilbert J, Cohen DN, Yarbrough WG, Zhao Z, Lovly CM.

NPJ Precis Oncol. 2019 Feb 15;3:5. doi: 10.1038/s41698-019-0077-2. eCollection 2019.

3.

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R.

Eur J Cancer. 2019 Jan;107:142-152. doi: 10.1016/j.ejca.2018.11.015. Epub 2018 Dec 18.

4.

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J.

JAMA Oncol. 2018 Nov 1. doi: 10.1001/jamaoncol.2018.4628. [Epub ahead of print]

PMID:
30383184
5.

Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.

Weiss J, Gilbert J, Deal AM, Weissler M, Hilliard C, Chera B, Murphy B, Hackman T, Liao JJ, Grilley Olson J, Hayes DN.

Oral Oncol. 2018 Sep;84:46-51. doi: 10.1016/j.oraloncology.2018.06.028. Epub 2018 Jul 19.

PMID:
30115475
6.

A Randomized Feasibility Trial to Evaluate Use of the Jaw Dynasplint to Prevent Trismus in Patients With Head and Neck Cancer Receiving Primary or Adjuvant Radiation-Based Therapy.

Zatarain LA, Smith DK, Deng J, Gilbert J, Dietrich MS, Niermann KJ, Ridner SH, Murphy BA.

Integr Cancer Ther. 2018 Sep;17(3):960-967. doi: 10.1177/1534735418784363. Epub 2018 Jun 28.

7.

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2018 May;16(5):479-490. doi: 10.6004/jnccn.2018.0026.

PMID:
29752322
8.

Management of treatment-related toxicities in advanced medullary thyroid cancer.

Brose MS, Bible KC, Chow LQM, Gilbert J, Grande C, Worden F, Haddad R.

Cancer Treat Rev. 2018 May;66:64-73. doi: 10.1016/j.ctrv.2018.04.007. Epub 2018 Apr 22. Review.

PMID:
29704768
9.

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.

Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Damian S, Hong RL, Le Tourneau C, Day D, Varga A, Elez E, Wallmark J, Saraf S, Thanigaimani P, Cheng J, Keam B.

Am J Clin Oncol. 2018 Feb 21. doi: 10.1097/COC.0000000000000429. [Epub ahead of print]

10.

Intracardiac Metastases Detected by 18F-FSPG PET/CT.

Magarik MA, Walker RC, Gilbert J, Manning HC, Massion PP.

Clin Nucl Med. 2018 Jan;43(1):28-30. doi: 10.1097/RLU.0000000000001883.

11.

Ectopic, retroperitoneal adrenocortical carcinoma in the setting of Lynch syndrome.

Wright JP, Montgomery KW, Tierney J, Gilbert J, Solórzano CC, Idrees K.

Fam Cancer. 2018 Jul;17(3):381-385. doi: 10.1007/s10689-017-0042-6.

PMID:
28940135
12.

Immunotherapy: Who Is Eligible?

Wang D, Gilbert J, Kim YJ.

Otolaryngol Clin North Am. 2017 Aug;50(4):867-874. doi: 10.1016/j.otc.2017.04.006. Review.

13.

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL Jr, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2017 Jun;15(6):761-770. doi: 10.6004/jnccn.2017.0101.

PMID:
28596256
14.

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R.

J Clin Oncol. 2017 May 10;35(14):1542-1549. doi: 10.1200/JCO.2016.70.1524. Epub 2017 Mar 22.

15.

Assessment of musculoskeletal impairment in head and neck cancer patients.

Ghiam MK, Mannion K, Dietrich MS, Stevens KL, Gilbert J, Murphy BA.

Support Care Cancer. 2017 Jul;25(7):2085-2092. doi: 10.1007/s00520-017-3603-1. Epub 2017 Feb 13.

PMID:
28191589
16.

E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.

Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B.

J Clin Oncol. 2017 Feb 10;35(5):490-497. doi: 10.1200/JCO.2016.68.3300. Epub 2016 Dec 28.

17.

A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.

Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J.

Invest New Drugs. 2017 Feb;35(1):95-104. doi: 10.1007/s10637-016-0406-z. Epub 2016 Nov 16.

18.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y.

ESMO Open. 2016 Sep 29;1(5):e000097. eCollection 2016. Review.

19.

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G; ESMO/ASCO Global Curriculum Working Group.

Ann Oncol. 2016 Aug;27(8):1378-81. doi: 10.1093/annonc/mdw239. No abstract available.

20.

Internal Lymphedema Correlates with Subjective and Objective Measures of Dysphagia in Head and Neck Cancer Patients.

Jackson LK, Ridner SH, Deng J, Bartow C, Mannion K, Niermann K, Gilbert J, Dietrich MS, Cmelak AJ, Murphy BA.

J Palliat Med. 2016 Sep;19(9):949-56. doi: 10.1089/jpm.2016.0018. Epub 2016 May 26.

21.

Neurocognitive function in patients with head and neck cancer undergoing primary or adjuvant chemoradiation treatment.

Bond SM, Dietrich MS, Gilbert J, Ely EW, Jackson JC, Murphy BA.

Support Care Cancer. 2016 Oct;24(10):4433-42. doi: 10.1007/s00520-016-3284-1. Epub 2016 May 25.

PMID:
27225527
22.

Using the galactose-α-1,3-galactose enzyme-linked immunosorbent assay to predict anaphylaxis in response to cetuximab.

Weiss J, Grilley Olson J, Deal AM, Chera B, Weissler M, Murphy BA, Hayes DN, Gilbert J.

Cancer. 2016 Jun 1;122(11):1697-701. doi: 10.1002/cncr.29978. Epub 2016 Mar 15.

23.

A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.

Chung CH, Rudek MA, Kang H, Marur S, John P, Tsottles N, Bonerigo S, Veasey A, Kiess A, Quon H, Cmelak A, Murphy BA, Gilbert J.

Oral Oncol. 2016 Feb;53:54-9. doi: 10.1016/j.oraloncology.2015.11.020. Epub 2015 Dec 17.

24.

Head and Neck Cancers, Version 1.2015.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M.

J Natl Compr Canc Netw. 2015 Jul;13(7):847-55; quiz 856.

25.

Medical education: perils and progress in educating and assessing a new generation of learners.

Gilbert J, Chew H, Dewey C, Horn L.

Am Soc Clin Oncol Educ Book. 2015:33-9. doi: 10.14694/EdBook_AM.2015.35.33. No abstract available.

26.

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.

Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD.

Lancet Oncol. 2015 Apr;16(4):426-35. doi: 10.1016/S1470-2045(15)70081-1. Epub 2015 Mar 18.

27.

Preliminary Testing of a Patient-Reported Outcome Measure for Recurrent or Metastatic Head and Neck Cancer.

Jackson LK, Deng J, Ridner SH, Gilbert J, Dietrich MS, Murphy BA.

Am J Hosp Palliat Care. 2016 May;33(4):313-20. doi: 10.1177/1049909115569591. Epub 2015 Feb 8.

PMID:
25667146
28.

A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.

Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyanon T, Leon ME, Neil Hayes D, Haigentz M Jr, Saba N, Nieva J, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH.

Oral Oncol. 2015 Apr;51(4):376-82. doi: 10.1016/j.oraloncology.2014.12.011. Epub 2015 Jan 13.

29.

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.

Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A.

Clin Cancer Res. 2015 Apr 1;21(7):1566-73. doi: 10.1158/1078-0432.CCR-14-2820. Epub 2015 Jan 8.

30.

Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Oct;12(10):1454-87.

31.

A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.

Puzanov I, Lindsay CR, Goff L, Sosman J, Gilbert J, Berlin J, Poondru S, Simantov R, Gedrich R, Stephens A, Chan E, Evans TR.

Clin Cancer Res. 2015 Feb 15;21(4):701-11. doi: 10.1158/1078-0432.CCR-14-0303. Epub 2014 Sep 11.

32.

Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.

Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W.

Oncologist. 2014 Jun;19(6):616-22. doi: 10.1634/theoncologist.2014-0011. Epub 2014 May 5.

33.

Patient enrollment onto clinical trials: the role of physician knowledge.

Gregg JR, Horn L, Davidson MA, Gilbert J.

J Cancer Educ. 2014 Mar;29(1):74-9. doi: 10.1007/s13187-013-0548-z.

PMID:
24163050
34.

Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines.

Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Aug;11(8):917-23. Erratum in: J Natl Compr Canc Netw. 2013 Dec 1;11(12):1458.

PMID:
23946171
35.

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.

Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA.

J Clin Oncol. 2013 Apr 10;31(11):1405-14. doi: 10.1200/JCO.2012.45.4272. Epub 2013 Mar 4.

36.

Impact of secondary lymphedema after head and neck cancer treatment on symptoms, functional status, and quality of life.

Deng J, Murphy BA, Dietrich MS, Wells N, Wallston KA, Sinard RJ, Cmelak AJ, Gilbert J, Ridner SH.

Head Neck. 2013 Jul;35(7):1026-35. doi: 10.1002/hed.23084. Epub 2012 Jul 12.

38.

Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.

Rosen LS, Puzanov I, Friberg G, Chan E, Hwang YC, Deng H, Gilbert J, Mahalingam D, McCaffery I, Michael SA, Mita AC, Mita MM, Mulay M, Shubhakar P, Zhu M, Sarantopoulos J.

Clin Cancer Res. 2012 Jun 15;18(12):3414-27. doi: 10.1158/1078-0432.CCR-11-3369. Epub 2012 Apr 17.

39.

Mucosal melanoma of the head and neck.

Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, Weber RS, Wolf G, Worden F; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Mar;10(3):320-38. No abstract available.

PMID:
22393194
40.

A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck.

Gilbert J, Rudek MA, Higgins MJ, Zhao M, Bienvenu S, Tsottles N, Chaudhry MA, Wahl R, Forastiere A, Gillison M.

Clin Cancer Res. 2012 Mar 15;18(6):1735-42. doi: 10.1158/1078-0432.CCR-11-2544. Epub 2012 Jan 23. Erratum in: Clin Cancer Res. 2012 Jul 15;18(14):3998. Chaudhry, Muhammad A].

41.

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.

Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen EE.

Clin Cancer Res. 2012 Apr 1;18(7):2056-65. doi: 10.1158/1078-0432.CCR-11-0563. Epub 2012 Jan 12.

42.

Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health.

Cooperstein E, Gilbert J, Epstein JB, Dietrich MS, Bond SM, Ridner SH, Wells N, Cmelak A, Murphy BA.

Head Neck. 2012 Jun;34(6):797-804. doi: 10.1002/hed.21816. Epub 2011 Aug 24.

PMID:
22127786
43.

Factors associated with the career choices of hematology and medical oncology fellows trained at academic institutions in the United States.

Horn L, Koehler E, Gilbert J, Johnson DH.

J Clin Oncol. 2011 Oct 10;29(29):3932-8. doi: 10.1200/JCO.2011.35.8663. Epub 2011 Sep 12.

44.

Oral cancers: supportive care issues.

Murphy BA, Gilbert J.

Periodontol 2000. 2011 Oct;57(1):118-31. doi: 10.1111/j.1600-0757.2011.00394.x. Review. No abstract available.

PMID:
21781183
45.

Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer.

Gilbert J, Murphy B, Dietrich MS, Henry E, Jordan R, Counsell A, Wirth P, Yarbrough WG, Slebos RJ, Chung CH.

Cancer. 2012 Feb 15;118(4):1007-13. doi: 10.1002/cncr.26364. Epub 2011 Jul 15.

46.

Head and neck cancers.

Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, Weber RS, Wolf GT, Worden F; National Comprehensive Concer Network.

J Natl Compr Canc Netw. 2011 Jun 1;9(6):596-650. Review. No abstract available. Erratum in: J Natl Compr Canc Netw. 2011 Jul;9(7):xxxiii.

PMID:
21636536
47.

Depression in patients with head and neck cancer and a functional genetic polymorphism of the serotonin transporter gene.

Gilbert J, Haman KL, Dietrich MS, Blakely RD, Shelton RC, Murphy BA.

Head Neck. 2012 Mar;34(3):359-64. doi: 10.1002/hed.21744. Epub 2011 May 20.

PMID:
21604315
48.

Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma.

Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough WG, Wheeler DL, Harari PM, Guo Y, Shyr Y, Slebos RJ, Chung CH.

PLoS One. 2010 Sep 13;5(9):e12702. doi: 10.1371/journal.pone.0012702.

49.

Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.

Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE.

Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):358-65. doi: 10.1158/1055-9965.EPI-09-0937. Epub 2010 Jan 19.

50.

A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.

Lin J, Gilbert J, Rudek MA, Zwiebel JA, Gore S, Jiemjit A, Zhao M, Baker SD, Ambinder RF, Herman JG, Donehower RC, Carducci MA.

Clin Cancer Res. 2009 Oct 1;15(19):6241-9. doi: 10.1158/1078-0432.CCR-09-0567. Epub 2009 Sep 29.

Supplemental Content

Loading ...
Support Center